Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.46 |
| ▸ | SUCNR1 | Q9BXA5 | 10/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | OXGR1 | Q96P68 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12895009 | 0.82 | PDE10A (0.49) | PDE10ASUCNR1ALDH1A1KDM4EMEN1 | |
| SCHEMBL17921385 | 0.79 | SUCNR1 (0.41) | PDE10ASUCNR1ALDH1A1OXGR1 | |
| SCHEMBL4823229 | 0.78 | ALDH1A1 (0.48) | PDE10ASUCNR1ALDH1A1KDM4EMEN1 | |
| SCHEMBL6129289 | 0.78 | KCNH2 (0.55) | PDE10ASUCNR1ALDH1A1OXGR1 | |
| SCHEMBL20487944 | 0.78 | PDE10A (0.43) | PDE10ASUCNR1ALDH1A1KDM4EMEN1 | |
| SCHEMBL23083184 | 0.77 | PDE10A (0.49) | PDE10ASUCNR1ALDH1A1KDM4EMEN1 | |
| SCHEMBL20156313 | 0.77 | HRH1 (0.50) | PDE10ASUCNR1ALDH1A1KDM4EMEN1 | |
| SCHEMBL28337161 | 0.77 | PDE10A (0.48) | PDE10ASUCNR1ALDH1A1KDM4EMEN1 | |
| SCHEMBL27705784 | 0.77 | PDE10A (0.48) | PDE10ASUCNR1ALDH1A1KDM4EMEN1 | |
| SCHEMBL27406008 | 0.77 | SUCNR1 (0.50) | SUCNR1KDM4EMEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200385384-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | SCHRÖDINGER, LLC | 2020-12-10 | — | — | US | disclosed |
| US-20200354359-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2020-11-12 | — | — | US | disclosed |
| WO-2020047239-A1 | INHIBITING αV β6 INTEGRIN | MORPHIC THERAPEUTIC, INC. (US) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200354359-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | PDE10A 4490/4885SUCNR1 2984/4885ALDH1A1 1504/4885 |
| US-20200385384-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | PDE10A 4490/4885SUCNR1 2984/4885ALDH1A1 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.